FDA Standardizing “Dear Doc” Letters To Fix Problems With Recipients As Much As Senders
Executive Summary
FDA appears to have found problems on both the senders’ and recipients’ sides of “Dear Health Care Provider Letters” and issued guidance recommending effectiveness assessments and formatting specifications in an attempt to give the correspondence more impact.
You may also be interested in...
Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining
Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.
FDA’s “Dear Doc” Final Guidance Yields To One Industry Request, Denies Another
Agency offers a sneak peek into final “Dear Health Care Provider Letters” guidance, decreasing some of industry’s burden, while refusing to cave on other requirements.